Undecimal Bio launches with $18M to take siRNA beyond liver disease
After spinning out one half of its business this summer, Eleven Therapeutics is carving out the other half with $18 million to join companies like Arrowhead and Alnylam that ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.